Malonyl-CoA Decarboxylase Inhibition as a Novel Approach to Treat Ischemic Heart Disease

Author： Lopaschuk Gary   Stanley William  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.20, Iss.6, 2006-12, pp. : 433-439

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmaceutical Interventions to Influence Arteriogenesis: New Concepts to Treat Ischemic Heart Disease

By  

Current Medicinal Chemistry, Vol. 13, Iss. 9, 2006-04 ,pp. : 979-987

Bentham Science Publishers

Access to resources Recommend Favorite

PARP inhibition: a novel approach to treat ischaemia/reperfusion and inflammation-related injuries

By Zhang J.  

Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. : 209-221

Informa Healthcare

Access to resources Recommend Favorite

Hypertension and Ischemic Heart Disease in Women

By  

Current Pharmaceutical Design, Vol. 22, Iss. 25, 2016-07 ,pp. : 3885-3892

Bentham Science Publishers

Access to resources Recommend Favorite

Malonyl CoA control of fatty acid oxidation in the newborn heart in response to increased fatty acid supply

By Sambandam Nandakumar   Onay-Besikci Arzu  

Canadian Journal of Physiology and Pharmacology, Vol. 84, Iss. 11, 2006-11 ,pp. : 1215-1222

NRC Research Press

Access to resources Recommend Favorite

Looking for novel ways to treat the hallmarks of Alzheimer's disease

By Stewart Alistair J   Fox Anthony   Morimoto Bruce H   Gozes Illana  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 8, 2007-08 ,pp. : 1183-1196

Informa Healthcare

Access to resources Recommend Favorite